Our results propose unprecedented therapeutic strategies for the treatment of CML aimed at overcoming and preventing drug resistance and progression to the current frontline BCR::ABL1 targeted therapies. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.